Pfizer Oncology: Who We Are and What We Do

One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find cures for this deadly disease.

OUR IMPACT

- 22 innovative cancer medicines and biosimilars, treating 30 types of cancer.
- 11 FDA Breakthrough Therapy Designations since 2013.
- Up to 13 potential approvals expected before the end of 2025.

BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES.

- Genitourinary Cancer: Leveraging a 15-year legacy to advance treatment for pervasive and hard-to-treat cancers.
- Colorectal Cancer: Targeting the aggressive biology of BRAF + metastatic colorectal cancer.
- Blood Cancer: Changing the treatment landscape for rare, life-threatening cancers.
- Lung Cancer: Advancing biomarker-driven therapies for the leading cause of cancer-related death.
- Melanoma: Delivering a precision medicine for mutation-driven, advanced melanoma.
- Biosimilars: Improving patient access to essential medicines.

We’ve made meaningful progress – but our work is far from finished. Millions of people are living with cancer, and millions more will receive a diagnosis in the future. They are the reason we will continue to work tirelessly to deliver on our purpose:

BREATHROUGHS THAT CHANGE PATIENTS’ LIVES.